TY - JOUR
T1 - Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system
AU - Aoyama, Katsuyuki
AU - Kuroda, Shinji
AU - Morihiro, Toshiaki
AU - Kanaya, Nobuhiko
AU - Kubota, Tetsushi
AU - Kakiuchi, Yoshihiko
AU - Kikuchi, Satoru
AU - Nishizaki, Masahiko
AU - Kagawa, Shunsuke
AU - Tazawa, Hiroshi
AU - Fujiwara, Toshiyoshi
N1 - Funding Information:
The authors would also like to thank Tomoko Sueishi and Tae Yamanishi for their excellent technical support. This work was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (grant number 12806418).
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Oncolytic virotherapy has the disadvantage of being unsuitable for systemic delivery due to immune elimination. Liposomal encapsulation is well-recognized to reduce immune elimination and enhance the stability of drugs in the bloodstream. In the present study, the potential of liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus (TelomeScan) expressing GFP (Lipo-pTS) as an oncolytic adenoviral agent suitable for systemic delivery was investigated. Lipo-pTS, which has a diameter of 40-50 nm, showed potent antitumor effects on HCT116 colon carcinoma cells in vitro and in vivo. Tumor selectivity of Lipo-pTS was independent of coxsackie and adenovirus receptor (CAR). Importantly, Lipo-pTS reduced production of adenovirus-neutralizing antibodies (AdNAbs) after intravenous administration into immune-competent mice compared to TelomeScan, and even in the presence of AdNAbs, Lipo-pTS maintained strong cytotoxicity. In conclusion, Lipo-pTS has the potential to become an oncolytic adenoviral agent suitable for systemic delivery with the characteristics of CAR-independent antitumor activity and a stealth effect on the immune system.
AB - Oncolytic virotherapy has the disadvantage of being unsuitable for systemic delivery due to immune elimination. Liposomal encapsulation is well-recognized to reduce immune elimination and enhance the stability of drugs in the bloodstream. In the present study, the potential of liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus (TelomeScan) expressing GFP (Lipo-pTS) as an oncolytic adenoviral agent suitable for systemic delivery was investigated. Lipo-pTS, which has a diameter of 40-50 nm, showed potent antitumor effects on HCT116 colon carcinoma cells in vitro and in vivo. Tumor selectivity of Lipo-pTS was independent of coxsackie and adenovirus receptor (CAR). Importantly, Lipo-pTS reduced production of adenovirus-neutralizing antibodies (AdNAbs) after intravenous administration into immune-competent mice compared to TelomeScan, and even in the presence of AdNAbs, Lipo-pTS maintained strong cytotoxicity. In conclusion, Lipo-pTS has the potential to become an oncolytic adenoviral agent suitable for systemic delivery with the characteristics of CAR-independent antitumor activity and a stealth effect on the immune system.
UR - http://www.scopus.com/inward/record.url?scp=85032512915&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032512915&partnerID=8YFLogxK
U2 - 10.1038/s41598-017-14717-x
DO - 10.1038/s41598-017-14717-x
M3 - Article
C2 - 29074882
AN - SCOPUS:85032512915
VL - 7
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 14177
ER -